Chapter 28 : New Developments in Diagnostics and Management of Invasive Candidiasis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

New Developments in Diagnostics and Management of Invasive Candidiasis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817176/9781555815394_Chap28-1.gif /docserver/preview/fulltext/10.1128/9781555817176/9781555815394_Chap28-2.gif


Invasive candidiasis is an infection of increasing prevalence which is associated with high morbidity and mortality. The rising incidence of invasive candidiasis is likely related to increasing numbers of immuno-compromised patients and lifesaving medical/surgical interventions that prolong life but break down both immunological and physical host defenses. The available tests include serologies focusing on the fungal cell wall components mannan, galactomannan, and (1,3)-ß-d-glucan (BG) or antibodies against these antigens, as well as genetic material detection tests. This chapter focuses on these new markers and their use for advanced prevention and treatment strategies. Research has shown that BG levels are not affected by colonization. Aside from BG, which is currently commercially available throughout the world, there is intense research for new biomarkers. This is driven by the fact that current diagnostic methods are less than optimal, by the interest of pharmaceutical companies in finding new surrogate markers for diagnosis and outcomes assessment for drug development trials, and by the recent interest of commercial diagnostic laboratories in these methods. Antifungal prophylaxis is an attractive strategy, as the best way to deal with a fungal infection is to prevent it from ever occurring.

Citation: Krishnan S, Ostrosky-Zeichner L. 2012. New Developments in Diagnostics and Management of Invasive Candidiasis, p 443-448. In Calderone R, Clancy C (ed), and Candidiasis, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817176.ch28
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Current strategies for the prevention and management of invasive fungal infections. doi:10.1128/9781555817176.ch28.f1

Citation: Krishnan S, Ostrosky-Zeichner L. 2012. New Developments in Diagnostics and Management of Invasive Candidiasis, p 443-448. In Calderone R, Clancy C (ed), and Candidiasis, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817176.ch28
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Akamatsu, N.,, Y. Sugawara,, J. Kaneko,, S. Tamura, and, M. Makuuchi. 2007. Preemptive treatment of fungal infection based on plasma (1→3)beta- d-glucan levels after liver transplantation. Infection 35: 346351.
2. Alexander, B. D. 2002. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl. Infect. Dis. 4 (Suppl. 3): 3237.
3. Arishima, T., and, J. Takezawa. Use of PCR based diagnosis for common invasive fungal infections in the intensive care unit. Nippon Ishinkin Gakkai Zasshi 47: 283288. (In Japanese.)
4. Cerikcioglu, N.,, B. Aksu,, T. D. Dal,, U. Deniz,, H. S. Bilgen,, E. Ozek, and, G. Söyletir. 2010. Seminested PCR for detection and identification of Candida species directly from blood culture bottles. New Microbiol. 33: 5762.
5. Chamilos, G.,, R. E. Lewis, and, D. P. Kontoyiannis. 2008. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis. 47: 503509.
6. Digby, J.,, J. Kalbfleisch,, A. Glenn,, A. Larsen,, W. Browder, and, D. Williams. 2003. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin. Diagn. Lab. Immunol. 10: 882885.
7. Einsele, H., and, J. Loeffler. 2008. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin. Microbiol. Infect. 14 (Suppl. 4): 3745.
8. Ellis, M.,, B. Al-Ramadi,, M. Finkelman,, U. Hedstrom,, J. Kristensen,, H. Ali-Zadeh, and, U. Hedstrom. 2008. Assessment of the clinical utility of serial beta- d-glucan concentrations in patients with persistent neutropenic fever. J. Med. Microbiol. 57 (Pt. 3) : 287295.
9. Fukazawa, Y. 1989. Antigenic structure of Candida albicans. Immunochemical basis of the serologic specificity of the mannans in yeasts. Immunol. Ser. 47: 3762.
10. Garey, K. W.,, M. Rege,, M. P. Pai,, D. E. Mingo,, K. J. Suda,, R. S. Turpin, and, D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43: 2531.
11. Girouard, G.,, C. Lachance, and, R. Pelletier. 2007. Observations on (1-3)-beta- d-glucan detection as a diagnostic tool in endemic mycosis caused by Histoplasma or Blastomyces. J. Med. Microbiol. 56 (Pt. 7) : 10011002.
12. Guery, B. P.,, M. C. Arendrup,, G. Auzinger,, E. Azoulay,, M. Borges Sa,, E. M. Johnson,, E. Müller,, C. Putensen,, C. Rotstein,, G. Sganga,, M. Venditti,, R. Zaragoza Crespo, and, B. J. Kullberg. 2009. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients. Part I. Epidemiology and diagnosis. Intensive Care Med. 35: 5562.
13. Kanamori, H.,, K. Kanemitsu,, T. Miyasaka,, K. Ameku,, S. Endo,, T. Aoyagi,, K. Inden,, M. Hatta,, N. Yamamoto,, H. Kunishima,, H. Yano,, K. Kaku,, Y. Hirakata, and, M. Kaku. 2009. Measurement of (1-3)-beta- d-glucan derived from different gauze types. Tohoku J. Exp. Med. 217: 117121.
14. Kedzierska, A. 2007. (1→3)-Beta- d-glucan—a new marker for the early serodiagnosis of deep-seated fungal infections in humans. Pol. J. Microbiol. 56: 39.
15. Lau, A.,, C. Halliday,, S. C. Chen,, E. G. Playford,, K. Stanley, and, T. C. Sorrell. 2010. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J. Clin. Microbiol. 48: 811816.
16. Lunel, F. M.,, M. A. Mennink-Kersten,, D. Ruegebrink,, H. A. van der Lee,, J. P. Donnelly,, N. M. Blijlevens, and, P. E. Verweij. 2009. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn. Microbiol. Infect. Dis. 64: 408415.
17. Maertens, J.,, D. Deeren,, D. Dierickx, and, K. Theunissen. 2006. Preemptive antifungal therapy: still a way to go. Curr. Opin. Infect. Dis. 19: 551556.
18. Maertens, J.,, K. Buve,, K. Theunissen,, W. Meersseman,, E. Verbeken,, G. Verhoef,, J. Van Eldere, and, K. Lagrou. 2009. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115: 355362.
19. Marty, F. M.,, C. M. Lowry,, S. J. Lempitski,, D. W. Kubiak,, M. A. Finkelman, and, L. R. Baden. 2006. Reactivity of (1→3)-beta- d-glucan assay with commonly used intravenous antimicrobials. Antimicrob. Agents Chemother. 50: 34503453.
20. Marty, F. M.,, S. Koo,, J. Bryar, and, L. R. Baden. (1→3)beta- d-glucan assay positivity in patients with Pneumocystis ( carinii) jiroveci pneumonia. Ann. Intern. Med. 147: 7072.
21. McMullan, R.,, L. Metwally,, P. V. Coyle,, S. Hedderwick,, B. McCloskey,, H. J. O’Neill,, C. C. Patterson,, G. Thompson,, C. H. Webb, and, R. J. Hay. 2008. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin. Infect. Dis. 46: 890896.
22. Mennink-Kersten, M. A.,, D. Ruegebrink, and, P. E. Verweij. 2008. Pseudomonas aeruginosa as a cause of 1,3-beta- d-glucan assay reactivity. Clin. Infect. Dis. 46: 19301931.
23. Miceli, M. H.,, M. L. Grazziutti,, G. Woods,, W. Zhao,, M. H. Kocoglu,, B. Barlogie, and, E. Anaissie. 2008. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46: 14121422.
24. Mitsutake, K.,, T. Miyazaki,, T. Tashiro,, Y. Yamamoto,, H. Kakeya,, T. Otsubo,, S. Kawamura,, M. A. Hossain,, T. Noda,, Y. Hirakata, and, S. Kohno. 1996. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J. Clin. Microbiol. 34: 19181921.
25. Morace, G.,, L. Pagano,, M. Sanguinetti,, B. Posteraro,, L. Mele,, F. Equitani,, G. D’Amore,, G. Leone, and, G. Fadda. 1999. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J. Clin. Microbiol. 37: 18711875.
26. Nakamura, H.,, M. Tateyama,, D. Tasato,, S. Haranaga,, S. Yara,, F. Higa,, Y. Ohtsuki, and, J. Fujita. 2009. Clinical utility of serum beta- d-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern. Med. 48: 195202.
27. Nakao, A.,, M. Yasui,, T. Kawagoe,, H. Tamura,, S. Tanaka, and, H. Takagi. 1997. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 44: 14131418.
28. Nett, J.,, L. Lincoln,, K. Marchillo, and, D. Andes. 2007. Beta-1,3 glucan as a test for central venous catheter biofilm infection. J. Infect. Dis. 195: 17051712.
29. Obayashi, T.,, H. Tamura,, S. Tanaka,, M. Ohki,, S. Takahashi,, M. Arai,, M. Masuda, and, T. Kawai. 1985. A new chromogenic endotoxin-specific assay using recombined Limulus coagulation enzymes and its clinical applications. Clin. Chim. Acta 149: 5565.
30. Obayashi, T.,, K. Negishi,, T. Suzuki, and, N. Funata. 2008. Reappraisal of the serum (1→3)-beta- d-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin. Infect. Dis. 46: 18641870.
31. Obayashi, T.,, M. Yoshida,, T. Mori,, H. Goto,, A. Yasuoka,, H. Iwasaki, and, A. Ito. 1995. Plasma (1→3)-beta- d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345: 1720.
32. Odabasi, Z.,, G. Mattiuzzi,, E. Estey,, H. Kantarjian,, F. Saeki,, R. J. Ridge,, P. A. Ketchum,, M. A. Finkelman,, J. H. Rex, and, L. Ostrosky-Zeichner. 2004. Beta- d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39: 199205.
33. Ohata, A.,, M. Usami,, T. Horiuchi,, K. Nagasawa, and, K. Kinoshita. 2003. Release of (1→3)-beta- d-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production. Artif. Organs 27: 728735.
34. Ostrosky-Zeichner, L.,, B. D. Alexander,, D. H. Kett,, J. Vazquez,, P. G. Pappas,, F. Saeki,, P. A. Ketchum,, J. Wingard,, R. Schiff,, H. Tamura,, M. A. Finkelman, and, J. H. Rex. 2005. Multicenter clinical evaluation of the (1→3) beta- d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41: 654659.
35. Pazos, C.,, J. Ponton, and, A. Del Palacio. 2005. Contribution of (1→3)-beta- d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J. Clin. Microbiol. 43: 299305.
36. Persat, F.,, S. Ranque,, F. Derouin,, A. Michel-Nguyen,, S. Picot, and, A. Sulahian. 2008. Contribution of the (1→3)-beta- d-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 46: 10091013.
37. Pfaller, M. A., and, D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20: 133163.
38. Pickering, J. W.,, H. W. Sant,, C. A. Bowles,, W. L. Roberts,, and G. L. Woods. 2005. Evaluation of a (1→3)-beta- d-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 43: 59575962.
39. Poulain, D.,, R. Robert,, F. Mesnard,, B. Sendid,, G. Lepage, and, D. Camus. 1997. Clearances of Candida albicans- derived alpha- and beta-linked mannose residues in sera from patients with candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 16: 1620.
40. Schuster, M. G.,, J. E. Edwards, Jr.,, J. D. Sobel,, R. O. Darouiche,, A. W. Karchmer,, S. Hadley,, G. Slotman,, H. Panzer,, P. Biswas, and, J. H. Rex. 2008. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann. Intern. Med. 149: 8390.
41. Sendid, B.,, M. Tabouret,, J. L. Poirot,, D. Mathieu,, J. Fruit, and, D. Poulain. 1999. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J. Clin. Microbiol. 37: 15101517.
42. Sendid, B.,, J. L. Poirot,, M. Tabouret,, A. Bonnin,, D. Caillot,, D. Camus, and, D. Poulain. 2002. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J. Med. Microbiol. 5: 433442.
43. Senn, L.,, J. O. Robinson,, S. Schmidt,, M. Knaup,, N. Asahi,, S. Satomura,, S. Matsuura,, B. Duvoisin,, J. Bille,, T. Calandra, and, O. Marchetti. 2008. 1,3-Beta- d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin. Infect. Dis. 46: 878885.
44. Shao, Q.,, L. Gao,, L. L. Wang,, Y. Ding,, H. Yang,, J. J. Suo,, D. X. Shen, and, L. Yu. 2010. Quantitative PCR for diagnosis of invasive fungal infections in patients with hematologic malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi 18: 499504. (In Chinese.)
45. Sims, C. R.,, J. Mohr,, V. Paetznick,, J. Rodriguez,, M. Finkelman, and, L. Ostrosky- Zeichner. 2006. Correlation of clinical outcomes with BG levels in patients with invasive candidiasis (IC), abstr. M-1599. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
46. Smith, P. B.,, D. K. Benjamin, Jr.,, B. D. Alexander,, M. D. Johnson,, M. A. Finkelman, and, W. J. Steinbach. 2007. Quantification of 1,3-beta- d-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin. Vaccine Immunol. 14: 924925.
47. Takesue, Y.,, M. Kakehashi,, H. Ohge,, Y. Imamura,, Y. Murakami,, M. Sasaki,, M. Morifuji,, Y. Yokoyama,, M. Kouyama,, T. Yokoyama, and, T. Sueda. 2004. Combined assessment of beta- d-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J. Surg. 28: 625630.
48. Tsuruta, R.,, H. Mizuno,, T. Kaneko,, Y. Oda,, K. Kaneda,, M. Fujita,, T. Inoue,, S. Kasaoka, and, T. Maekawa. 2007. Preemptive therapy in nonneutropenic patients with Candida infection using the Japanese guidelines. Ann. Pharmacother. 41: 11371143.
49. Wellinghausen, N.,, D. Siegel,, J. Winter, and, S. Gebert. 2009. Rapid diagnosis of candidaemia by real-time PCR detection of Candida DNA in blood samples. J. Med. Microbiol. 58 (Pt. 8) : 11061111.
50. Wisplinghoff, H.,, T. Bischoff,, S. M. Tallent,, H. Seifert,, R. P. Wenzel, and, M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39: 309317.
51. Zhao, L.,, J. Y. Tang,, Y. Wang,, Y. F. Zhou,, J. Chen,, B. R. Li, and, H. L. Xue. 2009. Value of plasma beta-glucan in early diagnosis of invasive fungal infection in children. Zhongguo Dang Dai Er Ke Za Zhi 11: 905908. (In Chinese.)


Generic image for table

Studies evaluating the diagnostic performance of BG for invasive candidiasis

Citation: Krishnan S, Ostrosky-Zeichner L. 2012. New Developments in Diagnostics and Management of Invasive Candidiasis, p 443-448. In Calderone R, Clancy C (ed), and Candidiasis, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817176.ch28

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error